Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

ImmunoScape, a Singapore-based developer of immune profiling technologies, said on Tuesday that it has raised $14 million in new funding.

OpGen subsidiary Curetis announced on Tuesday a research and development collaboration agreement with FIND, the global alliance for diagnostics, to develop the Unyvero A30 RQ platform for use in low and middle income countries.

Suzhou 4a Biotech Co., Ltd. has recently completed a Pre-A round of financing of tens of millions (CNY).

Roche announced on Monday that its Cobas Pure Integrated Solutions instrument has received 510(k) clearance from the US Food and Drug Administration.

Cancer detection startup Naveris said Monday it has secured a $33.4 million expansion of its Series A financing round to reach a total investment in the firm of $51 million that will be used to commercialize and advance its early, viral-driven cancer detection tests.

The domestic in vitro diagnostic (IVD) leader in the post-epidemic era is targeting India, which is growing as fast as the Chinese market. Fapon Biotech has been deployed in the Indian market for nearly 15 years, and the in vitro testing raw materials have more than half of the local market share.

BriaCell Therapeutics said that it has signed an agreement with Caris Life Sciences to support patient identification and enrollment of genetically defined subgroups for a current Phase I/II clinical trial in advanced metastatic breast cancer.

Qiagen announced on Thursday that it has obtained the CE-IVD mark for RT-PCR assays to detect and quantify Epstein-Barr virus and human herpesvirus-6 on its NeuMoDx instruments.

At the beginning of this year, Roche Diagnostics China and Changchun Sunostik Medical Technology Co., Ltd. entered into a strategic partnership and jointly launched a new RS600 laboratory automated system for the Chinese market.

NIMA Partners and EmpowerDx said Thursday they will jointly promote EmpowerDx's genetic test that helps determine a patient's risk for developing celiac disease.